معرفی
Georg Halder is a full professor at the Faculty of Medicine, KU Leuven, leading the Laboratory of Growth Control and Cancer Research (VIB-KU Leuven). He also serves as a member of the VIB-KU Leuven Center for Cancer Biology and contributes to strategic decision-making as a senior academic staff member in the Faculty of Medicine Council and Department of Oncology Council.
Research Focus: Halder's work centers on unraveling the molecular mechanisms of liver cancer progression and therapeutic resistance. His projects explore:
- Targeting Hippo and Oxytocin Receptor signaling to combat liver cancer heterogeneity
- Combination therapies for Ras/MAPK pathway resistance
- Role of P2Y6+ macrophages in pancreatic cancer liver metastasis
- Cell competition as a tumor suppression strategy
- TEAD inhibitors for clinical translation (licensed to Springworks Therapeutics)
Key Publications (2023-2025) highlight his contributions to Hippo pathway inhibition, liver cancer zonation, and cell competition dynamics. These studies employ advanced techniques like single-cell spatial multi-omics, Trypan Blue imaging, and CRISPR-based screening.
Scientific Impact: His research has led to a major licensing deal with Springworks Therapeutics for TEAD pathway inhibitors, with potential for $285M in milestone payments and clinical trials planned for 2024. He mentors students including Ana Algueró Nadal, Hanne Hillen, and Weronika Kowalczyk, fostering interdisciplinary training in cancer biology.
